Abbott Laboratories (NYSE:ABT) Shares Bought by Prairie Sky Financial Group LLC

Prairie Sky Financial Group LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 78,482 shares of the healthcare product maker’s stock after purchasing an additional 1,042 shares during the period. Abbott Laboratories comprises 5.4% of Prairie Sky Financial Group LLC’s portfolio, making the stock its 7th largest position. Prairie Sky Financial Group LLC’s holdings in Abbott Laboratories were worth $8,877,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Intech Investment Management LLC raised its position in shares of Abbott Laboratories by 10.0% in the 2nd quarter. Intech Investment Management LLC now owns 35,323 shares of the healthcare product maker’s stock valued at $3,670,000 after purchasing an additional 3,200 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in Abbott Laboratories by 4.5% in the second quarter. Thrivent Financial for Lutherans now owns 479,241 shares of the healthcare product maker’s stock valued at $49,799,000 after acquiring an additional 20,480 shares in the last quarter. Frank Rimerman Advisors LLC boosted its stake in Abbott Laboratories by 22,650.7% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 16,608 shares of the healthcare product maker’s stock valued at $1,726,000 after acquiring an additional 16,535 shares during the last quarter. 1832 Asset Management L.P. increased its position in shares of Abbott Laboratories by 115.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 161,505 shares of the healthcare product maker’s stock worth $16,782,000 after purchasing an additional 86,707 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its stake in shares of Abbott Laboratories by 1.7% in the 2nd quarter. Epoch Investment Partners Inc. now owns 60,703 shares of the healthcare product maker’s stock valued at $6,308,000 after purchasing an additional 988 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ABT. Barclays boosted their price objective on Abbott Laboratories from $143.00 to $149.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Morgan Stanley upped their price target on Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 17th. Royal Bank of Canada lifted their price objective on shares of Abbott Laboratories from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Jefferies Financial Group raised their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research report on Thursday, October 17th. Finally, Evercore ISI increased their price objective on shares of Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research note on Thursday, January 2nd. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $131.57.

Abbott Laboratories Trading Down 0.4 %

NYSE:ABT opened at $113.45 on Tuesday. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $121.64. The business has a fifty day moving average of $114.87 and a 200-day moving average of $112.95. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The stock has a market cap of $196.78 billion, a price-to-earnings ratio of 34.48, a PEG ratio of 2.43 and a beta of 0.73.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. This represents a $2.36 annualized dividend and a yield of 2.08%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 71.73%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.